Early trial of a new drug for advanced solid tumors and T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial is testing a new drug called GNTbm-38 for people with advanced solid tumors or a type of lymphoma called peripheral T-cell lymphoma (PTCL) that hasn't responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor or a type of peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to treatment.
- You have tried at least one standard treatment for your cancer, and it no longer works.
- You are able to do most of your daily activities (ECOG score 0-2).
- You have at least one tumor that can be measured on a scan (not in the brain).
- Your blood and organ function must be within certain limits, and you must weigh at least 50 kg with a BMI between 18 and 30.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SCTB39G, for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it can shrink tumors and improve survival, and to find the best dose. Participation involves regular treatment and check-ups.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination of two investigational drugs (SCTB41 and SCTB39G), sometimes given with standard treatment, for advanced solid tumors. The goal is to see if this approach can shrink tumors and control the cancer, and it may be an option for people who have exhausted standard treatments.
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Hear when a new Solid Tumor (Phase I) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.